Astellas Pharma (4503.T) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Astellas Pharma (4503.T) quarterly earnings & revenue
Astellas Pharma (4503.T) reported revenue of 3.31B JPY for Q4 2026, up 17.1% year-over-year, with net income of 268.66M JPY and diluted EPS of 0.15 JPY.
Over the last four reported quarters, Astellas Pharma generated 13.18B JPY in revenue and 1.80B JPY in net income.
Astellas Pharma's next earnings report is scheduled for August 5, 2026; analysts estimate EPS of 0.32 JPY.
Astellas Pharma quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q4 2026 | 3.31B JPY | +17.1% | 268.66M JPY | 0.15 JPY |
| Q3 2026 | 3.52B JPY | +10.4% | 617.93M JPY | 0.34 JPY |
| Q2 2026 | 3.23B JPY | +13.4% | 487.91M JPY | 0.27 JPY |
| Q1 2026 | 3.12B JPY | +6.9% | 421.44M JPY | 0.23 JPY |
| Q4 2025 | 2.83B JPY | +10.8% | 461.32M JPY | 0.26 JPY |
| Q3 2025 | 3.19B JPY | +22.6% | -601.53M JPY | -0.34 JPY |
| Q2 2025 | 2.85B JPY | +17.9% | 221.17M JPY | 0.12 JPY |
| Q1 2025 | 2.91B JPY | +26.2% | 231.61M JPY | 0.13 JPY |
Astellas Pharma (4503.T) — frequently asked questions
When does Astellas Pharma (4503.T) report earnings next?
Astellas Pharma is expected to report earnings on August 5, 2026. Analysts estimate EPS of 0.32 JPY.
What was 4503.T's revenue last quarter?
Astellas Pharma reported revenue of 3.31B JPY in Q4 2026, up 17.1% from the same quarter a year earlier.
What was 4503.T's EPS last quarter?
Astellas Pharma reported diluted EPS of 0.15 JPY in Q4 2026.
Is Astellas Pharma profitable?
Astellas Pharma is currently profitable, with 1.80B JPY in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)